Synthesis, Formation, and Occurrence of Contaminants in Biotechnologically Manufactured L-Tryptophan-Reference-Cited by-同舟云学术

Synthesis, Formation, and Occurrence of Contaminants in Biotechnologically Manufactured L-Tryptophan

Published:1999 Issue: Volume: Page:469-480
ISSN:0065-2598
Container-title:Advances in Experimental Medicine and Biology
language:
Short-container-title:

Author:

Simat T. J.,Kleeberg K. K.,Müller B.,Sierts A.

Publisher

Springer US

Link

http://link.springer.com/content/pdf/10.1007/978-1-4615-4709-9_59

Reference23 articles.

1. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte), 1995, Abwehr von Arzneimittelrisiken— L-Tryptophan-haltige Arzneimittel, Berlin, Bescheid vom 13:12.

2. Brown, R.R., Fisrtte, P.L., Arend, R.A., and Ozaki, Y., 1994, Altered tryptophan metabolism and immune parameters in eosinophilia-myalgia syndrome, in: L-Tryptophan: Current Prospects in Medicine and Drug Safety. W. Kochen and H. Steinhart, eds.pp. 255–262, de Gruyter, Berlen.

3. Dabre, T., Nussbaumer, C., and Borschberg, H.-J., 1984, Synthesis of (-)-horbatine and related indole alkaloids, Helv. Chem. Acta, 67:1038–1051.

4. Goda, Y., Suzuki, J., Maitani, T., Yoshihira, K., Takeda, M., and Uchiyama, M., 1992, 3-Anilino-L-alanine, structural determination of UV-5, a contaminant in EMS-associated L-tryptophan samples, Chem. Pharm. Bull., 40:2236–2238.

5. Gray, R.A., 1959, Preparation and properties of 3-indoleacetaldehyde, Arch. Biochem. Biophys., 81:480–488.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eosinophilia–myalgia syndrome;Encyclopedia of Toxicology;2024

2. Eosinophilia–Myalgia Syndrome;Encyclopedia of Toxicology;2014

3. Improving Regulatory Decisions through Targeted Research: A Case Study Concerning Amino Acids;European Journal of Risk Regulation;2012-06

4. Adverse Drug Reactions: History, Terminology, Classification, Causality, Frequency, Preventability;Stephens' Detection and Evaluation of Adverse Drug Reactions;2012-01-30

5. Preventability of Drug-Related Harms – Part II;Drug Safety;2010-11